and T helper 17 cells, have important roles in the human periodontium. However, the basis for Treg cytokine expression in various compartments of the periodontium remains unclear. The aim of the present study was to investigate the expression of interleukin (IL)-35 in the peripheral blood mononuclear cells (PBMCs) and periodontal tissues of patients with chronic periodontitis (CP), with a view to understanding its role in this disease, and ultimately providing improved treatments. Peripheral blood, periodontal tissues and gingival crevicular fluids (GCFs) were collected from patients with CP or impacted teeth, the latter serving as healthy controls. The expression levels of IL-35 subunit mRNAs in PBMCs and periodontal tissues were determined using reverse transcription-quantitative polymerase chain reaction, while the IL-35 protein expression in GCFs and sera was quantified by ELISA. The relative expression of IL-35 subunit mRNAs in the affected tissues of patients with CP was significantly higher compared with that in samples from healthy controls (P<0.05). The mean concentration of IL-35 protein in the GCFs and sera of patients with periodontitis was also significantly higher compared with that in samples from healthy controls (P<0.001). IL-35 protein and periodontal clinical indicators were negatively correlated. It was hypothesized that the increased level of IL-35 plays a protective role in periodontal disease by maintaining immune system homeostasis and dampening the inflammatory response, and highlights IL-35 as a potential new therapy for the treatment of periodontitis.
Introduction
Chronic periodontitis (CP) is an infectious disease that affects the periodontium and gradually destroys periodontal tissues (1) . Bacterial plaque is a well-known cause of CP, which stimulates a local inflammatory response and activation of the innate immune system (1, 2) . This eventually results in the characteristic pathology of periodontal disease, the main clinical features of which are advancing gingival inflammation, irreversible alveolar bone loss, and the loosening and/or loss of teeth (3) . Numerous studies (4, 5) have highlighted the role of T lymphocyte cells in periodontitis; in particular, T lymphocyte phenotype and function are important in the susceptibility, onset and severity of periodontitis (6) .
Regulatory T (Treg) cells are a critical sub-population of CD4 + T cells that are essential for maintaining self-tolerance and preventing autoimmunity, for limiting chronic inflammatory diseases, and for regulating homeostatic lymphocyte expansion (7) (8) (9) (10) (11) . A recent study by Wang et al (12) demonstrated that the imbalance between Treg cells and T helper 17 (Th17) cells plays an essential role in the progression of periodontitis.
Interleukin (IL)-35, as a Forkhead box P3 (Foxp3) + Treg cell immunosuppressive/anti-inflammatory cytokine, is required for the maximum regulatory activity of Treg cells (13) . IL-35 is a heterodimer formed by an IL-12p35 subunit and an IL-27β chain, the latter of which is encoded by the Epstein-Barr virus-induced 3 (EBi3) gene (14) . The known functions of IL-35 include: Maintenance of the peripheral immune system; regulation of the proliferation of T effector cells; inhibition of Th17 cell differentiation and IL-17 synthesis (15) . Thus, it has a close association with immunological and infectious diseases (16, 17) . Although studies on IL-35 are relatively few, and the signal transduction mechanisms involved in its actions are not yet elucidated, IL-35 therapy shows promising potential for the treatment of immunological and infectious diseases (15, 18) .
In the present study, the expression of Foxp3, IL-12p35 and EBi3 mRNA in peripheral blood mononuclear cells (PBMCs) and periodontal tissue, and the concentration of IL-35 protein in serum and gingival crevicular fluid (GCF), were compared between patients with CP and healthy individuals. Elucidating the potential signaling mechanisms of IL-35 in CP may provide a basis for improvements in the future clinical treatments of periodontitis.
Materials and methods
Study population. The study included 20 patients with CP (the CP group) and 20 healthy individuals (the control group) at Shengjing Hospital of China Medical University (Shenyang, China). Participants were recruited from February to December 2013, and their ages ranged from 18 to 55 years. Subjects were included according to the following three criteria: i) A diagnosis of moderate to severe chronic periodontitis [moderate: 4 mm<pocket depth (PD) ≤6 mm and clinical attachment loss (CAL) 3-5 mm, or radiographic bone loss between one-third and one-half root length; severe: PD>6 mm and CAL>5 mm, or radiographic bone loss ≥ one-half root length (19) ]; ii) retention of ≥20 teeth; iii) being generally healthy and without systemic disease. Exclusion criteria included: i) Recent intake of any pharmaceutical that had the potential to influence the outcome of the study or inflammatory clinical indices, e.g. antibiotics; ii) use of systemic antibiotics or local antimicrobial agents in the previous 3 months prior to the start of the trial; iii) pregnancy or lactation in female subjects; iv) received periodontal supportive treatment within 6 months prior to the start of the trial. The study protocol was approved by the Ethics Committee of Shengjing Hospital of China Medical University. All trial participants provided informed consent.
Clinical examination. To diagnose and document periodontal disease, trial participants were assessed for probing depth (PD) and clinical attachment level (CAL) by a single examiner using a Florida Probe system (Florida Probe Corporation, Gainesville, FL, USA). Testing was conducted for six sites per tooth for all teeth.
GCF and periodontal tissue collection.
A tooth site without untreated caries, overhang fillings, food impaction or any inflammation with the exception of CP in each quadrant was selected. In the majority of cases the mesiobuccal site of the first molar was selected. If the first molar was not available, a second molar or a premolar in the same quadrant was selected. Plaque and chunks of calculus were removed and the tooth was then dried with dry, sterile cotton and an air gun. After waiting for 1 min, a Whatman paper strip was inserted, until mild resistance was encountered, for GCF collection from a periodontal pocket. Each paper strip was left in its position for 30 sec. Paper strips contaminated with blood were discarded. Four paper strips were collected from each participant (a total of 80 sites from the CP or control groups) and inserted into an Eppendorf tube, 200 µl PBS added and the tubes were then stored at -80˚C.
Patients received local anesthesia and periodontal tissue biopsies were obtained by surgical excision from the labial/buccal surface of the gingival margin/papilla of multirooted teeth. Tissue biopsies from patients with periodontitis were collected with flap surgery. Healthy biopsies were also collected from patients following surgery for impacted teeth. Each tissue was repeatedly washed with 0.9% saline until blood was no longer seen, then 1 ml of RNAiso Reagent (Takara Biotechnology Co., Ltd., Dalian, China) was added to each sample and the sample was stored in an RNase-free Eppendorf tube at -80˚C.
Blood collection. Peripheral venous blood was drawn from each individual and collected in heparin tubes. PBMCs were isolated from 2 ml blood by density gradient centrifugation using the separation medium Ficoll according to the manufacturer's instructions (Haoyang Biotechnology Co., Ltd., Tianjin, China). Peripheral blood taken at rest was centrifuged (20˚C, 400 x g for 20 min) and serum aspirated into new tubes. PBMCs and sera were separately stored at -80˚C until use.
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). PBMCs or 1-mm
3 periodontal tissue samples were processed for total RNA extraction in 1 ml RNAiso Reagent at 4˚C. RNA quality was determined using a bioanalyzer and total RNA was quantified using a spectrophotometer (Applied Biosystems; Thermo Fisher Scientific, Inc., Waltham, MA, USA) at A 260nm /A 280nm between 1.8 and 2.0. RT was performed using a PrimeScript RT system (Takara Biotechnology Co., Ltd.) following the manufacturer's recommendations. The expression levels of I Foxp3, IL-12p35, EBi3 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) transcripts were quantified using RT-qPCR with SYBR Premix Ex Taq II (TaKaRa Biotechnology Co. Ltd.) and a LightCycler system (Roche Molecular Biochemicals, Mannheim, Germany) in accordance with the manufacturer's protocol. Primers for Foxp3, IL-12p35, EBi3 and GAPDH are listed in Table I . Cycling conditions used were: 95˚C for 30 sec, 95˚C for 5 sec and 60˚C for 34 sec for 40 cycles, then 95˚C for 15 sec, 60˚C for 1 min and 95˚C for 15 sec. In the qPCR process, 2 µl cDNA was added per well, using three wells per sample. Relative target gene quantification was obtained according to the 2 -ΔΔCq method (12) . Target gene mRNA expression was normalized to GAPDH mRNA expression, and the adjusted expression for healthy individuals was used as a reference (fold change, 1). In the mRNA analysis, 20 patients per group were included.
Enzyme-linked immunosorbent assay (ELISA)
. Sera and GCFs were tested using an IL-35 ELISA kit (USCN, Co., Ltd., Wuhan, China) in strict accordance with the manufacturer's instructions. The optical density of each sample was determined at 450 nm. A standard curve was generated, and data were expressed in units of pg/ml IL-35 per liter of serum or GCF.
Statistical analysis. Data are expressed as the mean ± standard error of the mean for each group. An unpaired Student's t-test was used to analyze differences between groups using SPSS 
Results

Patient information and clinical parameters.
A total of 40 participants were included in this study, with an age range from 18 to 55 years. Fig. 3 show the mean levels of IL-35 protein in GCF and serum samples from the CP and healthy control groups. The mean concentration of IL-35 protein was 205.56±1.61 ng/ml in GCF and 330.42±4.30 ng/ml in serum from the CP group, while for the healthy control group it was 101.88±0.37 ng/m in GCF and 206.89±10.06 ng/ml in serum. The mean concentration of IL-35 protein in the GCF and serum was significantly higher for the CP group compared with the healthy group (P<0.001 for both).
IL-35 protein in GCF and serum.
Correlation analysis. Using the Pearson rank correlation test, the concentration of IL-35 in the GCF with the CAL at detection sites of the CP group exhibited a negative correlation (P<0.001, R 2 =0.6101; Fig. 4A ), and the concentrations of IL-35 and PD at detection sites were also significantly negative correlation (P<0.001, R 2 =0.6173; Fig. 4B) . Similarly, the concentration of IL-35 in the serum of the CP group with CAL at detection sites exhibited a negative correlation (P<0.001, R 2 = 0.9119; Fig. 4C ), and PD at detection sites was also negatively correlated with the concentration of serum IL-35 (P<0.001, R 2 =0.6812; Fig. 4D ).
Discussion
Treg cells are necessary in the maintenance of immune homeostasis and the prevention of autoimmune disease. There is evidence (20, 21) to suggest that anti-inflammatory Treg cells also play an important role in the development of periodontal disease and are involved in the subsequent inflammation and bone resorption. The infiltration of Treg cells into periodontal tissue reflects their ability to inhibit tissue damage (22) . Foxp3 plays an integral role in regulating the differentiation of Treg cells (23) . In the present study, Foxp3 was detected in periodontal tissues and PBMCs using RT-qPCR and its expression was found to be significantly higher in the CP group compared with the healthy control group. IL-35 is an immunosuppressive/anti-inflammatory cytokine, expressed by Foxp3 + Treg cells, that belongs to the IL-12 family of cytokines (24) . IL-35 is a dimeric protein comprised of an α chain (p35) and a β chain (EBi3) (14) . Unlike other cytokines of the IL-12 family, IL-35 acts as an inhibitory factor for chronic inflammation, autoimmune disease and other immune disorders (7), and the expression of IL-35 in Treg cells is associated with their immune inhibitory ability (25) . It has also been suggested that IL-35, as an inhibitory cytokine, plays a central role in infection and immune regulation (26) , which includes inhibiting the proliferation of T cells and their effects. In the present study, it was observed that IL-35 was strongly detected in periodontitis tissues and the expression of IL-35 protein was increased in tissues from the CP group compared with those of healthy controls.
As long-living, non-Foxp3-dependent cells within the body, IL-35-producing inducible Treg cells secrete IL-35, which may inhibit the spread of inflammation, increase the number of Treg cell subsets and enhance immune regulation (27) . Niedbala et al (15) found that an EBi3-p35-Fc fusion protein promoted the proliferation of CD4 + CD25 + Treg cells and inhibited CD4 + CD25 -T cells in vitro. These observations may explain why as increased expression of IL-35 protein in tissues from the CP group compared with those of healthy controls was detected in the present study.
There is evidence indicating that a loss of IL-35 is associated with the progression of various diseases, including numerous inflammatory diseases (28, 29) . IL-35 is required for effective Treg cells; animals lacking functional IL-35 exhibit an enhanced inflammatory immune response and progressive deterioration from disease (30, 31) . The present study found that the concentration of IL-35 in the GCF of the CP group 
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showed a negative correlation with CAL or PD in detection sites, and the concentration of IL-35 in the serum of the CP group correlated with CAL and PD in a similar manner. These data suggest that IL-35 in autoimmune or infectious diseases may regulate the local microenvironment and peripheral immune response, maintaining its homeostasis. The analysis of IL-12p35 and EBi3 (IL-35) mRNAs using RT-qPCR in PBMCs and periodontal tissues from patients with CP in the present study revealed significantly higher expression in the CP group compared with the healthy control group. This is a similar result to that of Kalburgi et al, which to the best of our knowledge is the only other study to address the role of IL-35 in periodontal disease, albeit using semi-quantitative RT-PCR (32) . The present study also found that the mean concentration of IL-35 protein in GCFs and sera from the CP group was significantly higher than for the healthy group, paralleling gene expression. These results suggest that IL-35 is an essential factor for the immune response of Treg cells, and may be useful in the prognosis of CP. Similarly, Nakajima et al (33) reported that the proportion of CD4 + CD25 + T cells and Foxp3 expression in periodontal disease tissues was increased compared with those of gingivitis controls. Since EBi3 is a downstream target of Foxp3 (7), the high expression of Foxp3 mRNA, as detected in the present study, would promote EBi3 subunit formation and therefore explain the high IL-35 protein expression that was observed.
The results of the present study indicate that IL-35 expression increases with CP development, which may help to attenuate the process of chronic periodontitis. In addition, although patients included in the study did not exhibit systemic disease, periodontitis may cause, or aggravate, chronic inflammation in systemic disease. More specifically, gram-negative anaerobic bacteria at the bottom of periodontal pockets may invade epithelial cells and hide in host cells, aggravating the destruction of periodontal tissue; they can potentially also invade endothelial cells and access the blood circulation to stimulate a host immune response and cause systemic inflammation (34) (35) (36) . IL-35, as a negative regulator of immune factors, may slow or inhibit the development of periodontal disease and thus, indirectly, also slow systemic disease. IL-35 is a relatively recently identified cytokine that has not been studied in many disease models. Since the parameters investigated in the present study are few, it is unclear whether IL-35 enhances or antagonizes the effects of other cytokines or immune cells in CP. In future, it will be necessary to increase sample sizes and study a greater number of parameters to more fully understand the role of IL-35 in CP.
IL-35, as a Treg-specific suppressor of inflammatory cytokines, may maintain the balance between bacterial infection in chronic periodontal patients and effector cells by regulating the immune system, in order to avoid periodontal tissue damage caused by an overstimulated immune system (24, 32) . The detection of higher levels of IL-35 protein and subunit mRNA in diseased tissue compared with healthy tissue indicate that it may play an important role in the development of CP. As GCF is easily sampled, and simple, sensitive and reliable detection methods for IL-35 are available, IL-35 is potentially an important diagnostic tool for clinical use. However, as an appropriate treatment strategy for periodontitis, further studies on IL-35 are required to understand the precise functional role of this cytokine in periodontal disease and within immune and inflammatory regulatory networks.
